Remove services
article thumbnail

FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors

Health Law Advisor

Food and Drug Administration (“FDA”) released final guidance on informed consent for clinical investigations (“Final Guidance”). This update follows FDA’s draft guidance, which was issued in July 2014, and supersedes the FDA’s “A Guide to Informed Consent,” which was issued in September 1998.

article thumbnail

AI’s Ability to Manipulate Decision Making Requires a Moratorium on Its Use in Obtaining Consent for Biomedical Research

Bill of Health

The federal government’s commitment to assuring that participants in human subject research provide fully informed consent dates back to the U.S In 2017, Congress acted again to update the Common Rule and strengthen the provisions related to consent. While the U.S. These warnings echo those of the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine

Bill of Health

By Adithi Iyer The cultural, informational, and medical phenomenon that is 23andMe has placed a spotlight on precision medicine, which seeks to personalize medical care to each patient’s unique makeup. In other words, could a corporate, direct-to-consumer cell-based testing service be the next 23andMe? Our Cells in Whose Hands?

FDA 277
article thumbnail

Important practice-points for pharmacists independently initiating and furnishing Paxlovid

Natalia Mazina

Recently – on July 6, 2022 – the FDA amended the Emergency Use Authorization (EUA) for Paxlovid, an orally-administered COVID-19 therapeutic drug. Recently – on July 6, 2022 – the FDA amended the Emergency Use Authorization (EUA) for Paxlovid, an orally-administered COVID-19 therapeutic drug.

article thumbnail

Protecting the Consumer at the Heart of DTC Precision Medicine

Bill of Health

By Adithi Iyer In my last piece , I discussed the hypothetical successor of 23andme — a tissue-based direct-to-consumer testing service I’ve called yourtissueandyou — and the promise and perils that it might bring in consumer health information and privacy. Consumer protections for this type of information are, in a word, complicated.

HIPAA 157
article thumbnail

Introducing Affiliated Researchers for the Project on Psychedelics Law and Regulation

Bill of Health

is a service-oriented, curious Ghanaian native passionate about the intersections of community, wellbeing, and technology. Justin is currently engaged in clinical work seeking to expand the reach of harm reduction services in New Haven. We look forward to learning from and sharing their insights with our audiences.

FDA 144
article thumbnail

OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers

Healthcare Law Blog

On Thursday, March 16, the Office of the Inspector General for the Department of Health and Human Services (“OIG”) issued OIG Advisory Opinion (“AO”) No. The Therapy is available only for clinical use under an FDA-approved, Category B Investigational Device Exemption (“IDE”) ( see 42 CFR 405.211(b)-(c) ).